ÂÜÀòÂÒÂ×

Andrew Combs, Ph.D. is the Executive Vice President and Head of Chemistry at Prelude Therapeutics. Dr. Combs joined Prelude in 2019 and has over 23 years of experience as a medicinal chemist. Prior to joining Prelude, Dr. Combs previously held several roles at Incyte Corporation, most recently as Vice President of Discovery Chemistry, where he led teams in medicinal chemistry, analytical chemistry, enabling technologies, computational design, and informatics from 2003 until 2019. Earlier in his career, Dr. Combs held positions of increasing responsibility, starting as a Senior Research Scientist and advancing to a Director of medicinal chemistry at DuPont-Merck, DuPont Pharmaceuticals, and Bristol-Myers Squibb. His passion for research embraces the application of innovative and enabling technologies to expedite the drug discovery process. He has led teams of creative chemists with whom he co-invented >10 clinical candidates, including epacadostat and parsaclisib, which both entered late stage clinical trials in oncology. Dr. Combs holds B.S. degrees in Chemistry and Molecular Biology from the UW-Madison, a Ph.D. in Organic Chemistry from UCLA, and completed his training as a HHMI post-doctoral fellow at Harvard University.